RxDoctor Payments Data

Arthur Yee, MD

Rheumatology · New York, NYNPI 1164485298

Payments from drug & device makers

$5,844in general payments, 2019–2025

Across 23 payments — averaging $254.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$3K
  • Amgen$2K
  • Nevro Corp.$165
  • AbbVie$146
  • Boehringer Ingelheim$103
  • Lilly USA, LLC$48
  • plus $75 from 3 others

What the payments were for

  • Consulting fees$401%
  • Speaking & faculty fees$4,17571%
  • Travel & lodging$93116%
  • Food & beverage$69812%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,844 in reported general payments places this provider in the 55th percentile of 541 rheumatology providers in New York.

See all rheumatology providers in New York

Medicare billing

Part B allowed, 2024
$347,474
Medicare patients
342
Services billed
26,031

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab35$526,534
Humira(Cf)Adalimumab16$415,684
Enbrel SureclickEtanercept26$233,842
EnbrelEtanercept25$205,784
RinvoqUpadacitinib31$191,090
OtezlaApremilast36$190,673
ActemraTocilizumab17$148,172
XeljanzTofacitinib Citrate11$73,930
Evenity (2 Syringes)Romosozumab-Aqqg16$48,462
ProliaDenosumab13$22,146
Colchicine93$17,656
Celecoxib66$4,707
Mycophenolate Mofetil14$4,617
Hydroxychloroquine Sulfate108$4,461
MethotrexateMethotrexate Sodium127$3,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieHumira(Cf), Rinvoq$146$606,77447 claims
AmgenEnbrel, Otezla, Evenity (2 Syringes), Prolia$1,943$467,06590 claims
PfizerXeljanz$18$73,93011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 541 rheumatology providers in New York.

Other rheumatology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →